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Abstract
Background: Neutrophils are critical in the defense against potentially harmful microorganisms,
but their excessive and inappropriate activation can contribute significantly to tissue damage and a
worsening pathology. Through the release of endocrine factors submandibular glands contribute to
achieving a balance in neutrophil function by modulating the state of activation and migratory
potential of circulating neutrophils. A putative hormonal candidate for these effects on neutrophils
was identified as a heptapeptide named submandibular gland peptide T (SGP-T; sequence =
TDIFEGG). Since the tripeptide FEG, derived from SGP-T, and its D-amino acid analogue feG had
similar inhibitory effects on inflammatory reactions, we investigated the effects of feG on human
and rat neutrophil function.
Results: With human neutrophils feG had no discernible effect on oxidative burst or phagocytosis,
but in picomolar amounts it reduced PAF-induced neutrophil movement and adhesion, and the
binding of CD11b by 34% and that of CD16b close to control values. In the rat feG (10-11M)
reduced the binding of CD11b and CD16 antibodies to PAF-stimulated circulating neutrophils by
35% and 43%, respectively, and at 100 micrograms/kilograms intraperitoneally feG reduced
neutrophil in vivo migration by 40%. With ovalbumin-sensitized rats that were challenged with
antigen, feG inhibited binding of antibodies against CD16b but not CD11b, on peritoneal
leukocytes.
Conclusions:  The inhibitory effect of feG on neutrophil movement may be mediated by
alterations in the co-stimulatory molecules CD11b and CD16.
Background
The VCS-1 gene encodes a multipotent prohormone as a
146 amino acid protein named SMR1 [1]. From proximal
N-terminal dibasic cleavage sites a pentapeptide, QHNPR,
is generated that is involved in the modulation of mineral
balance [2], whereas from the carboxyl-terminus a 7 ami-
no acid peptide (TDIFEGG; SGP-T) is an inhibitor of en-
dotoxic hypotension [3] and intestinal anaphylaxis [4].
This heptapeptide can be shortened to a biologically ac-
tive pentapeptide (FEGGG) or tripeptide (FEG) [4]. The
conversion of the tripeptide into its D-isomeric form
(feG) favors its oral administration, yielding a significant
reduction in anaphylactic responses of the intestine, heart
and lungs [5,6]. The anti-inflammatory effects of these
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salivary gland peptides have been postulated in animal
models to be due to the inhibitory effects on neutrophil
chemotaxis [7,8] and leukocyte rolling [9], although rela-
tively little is known of the effects of these peptides on hu-
man neutrophils.
Neutrophils participate in the first line of defense against
potentially harmful microorganisms [10,11], but they
also contribute to the underlying pathology associated
with acute lung [12], ischemia-reperfusion [13] and burn
[14] injuries, arthritis [15], and allergic reactions [16,17].
The repertoire of defense mechanisms deployed by the
neutrophil includes production of reactive oxygen species,
proteolytic enzymes, and bactericidal peptides [10,11],
that can contribute significantly to tissue damage and sub-
sequent pathology over and above that caused by the orig-
inal infection or injury. Therefore, the modulation of
neutrophil activities constitutes an approach to regulate
inflammatory responses, with the desired effect being a
balance between the protective and tissue repair proper-
ties of neutrophils and their tissue destroying potential.
The SMR1 C-terminal peptides possibly represent hor-
mones whose primary functions are to down regulate leu-
kocyte function, but not to the extent that they suppress
innate immune function and compromise their protective
role in disease [18,19]. In this study we examined the ef-
fects of feG on several human neutrophil functions, and
correlated these with the actions of feG on inflammatory
events in rodents. The results suggest that feG, through ac-
tions on CD11b and CD16, exerts its anti-inflammatory
effects by modulating primarily neutrophil adhesion and
migratory responses while leaving other neutrophil func-
tions unaltered.
Results
Effect of feG on neutrophil migration
Between 10 to 25% of the neutrophils added to the Costar
upper chamber migrated into the bottom chamber in re-
sponse to 10-9M PAF. The effects of different doses of feG
on the migration of human neutrophils were examined
over a 2 h period (Figure 1). feG, at doses ranging from 10-
11M to 10-9M, inhibited by 30 to 40% neutrophil migra-
tion elicited by PAF (10-9M). At doses outside this range
the inhibitory effect was absent, resulting in a bell-shaped
dose-response relationship.
Inhibition of neutrophil adhesion by feG
The effect of feG, in the dose range of 10-12M to 10-8M, on
neutrophil adhesion to gelatin coated slides was evaluat-
ed. Under basal conditions and after 30 min of incuba-
tion, approximately 7.6 ± 1.1% of the added neutrophils
adhered firmly, and this basal adhesion was not altered by
feG (Figure 2A). If the neutrophils were stimulated with
10-9M PAF, just prior to adding the neutrophils to the
slides, adhesion increased by 64% from basal to 12.4 ±
1.4%, and feG at 10-11M and 10-10M inhibited neutrophil
adhesion by 36% and 27%, respectively (Figure 2B). In
another study we found that feG (10-9M) inhibited by
61.8 ± 17.7% (n = 3) eosinophil binding to gelatin, while
having no effect on the binding of these cells to fibronec-
tin (5.7 ± 7.1% inhibition; n = 5).
Effect of feG on superoxide production and phagocytosis
Through the release of superoxide and enzymes and by
phagocytosis, neutrophils inactivate and destroy virulent
pathogens [11]. The effects of feG on these functions were
evaluated. Basal release of superoxide was 17.0 ± 2.9 7
µmoles/107 cells/min, and in response to PAF (10-9M)
human neutrophils generated 60.6 ± 8.7 µmoles of O2/
107 cells/min. In the dose ranges of 10-8M to 10-12M feG
superoxide production remained unchanged (54.1 ± 6.7
µmoles of O2/107 cells/min with 10-11M feG). feG did not
alter phagocytosis of opsonized S. aureus (not shown).
Cell adhesion associated molecules on human neutrophils
The effect of feG on the binding of antibodies to cell sur-
face markers that are related to cell migration and adhe-
sion were examined. Of the several adhesion molecules
responsible for neutrophil adhesion, rolling and transcel-
lular migration, we examined CD11b initially. PAF (10-
9M) increased the binding of CD11b antibody to neu-
trophils from a basal MFI, with untreated cells at 37°C,
from 148.1 ± 12.8 to 291.6 ± 14.1. Incubating the neu-
trophils with feG alone did not affect binding of CD11b
antibody, however if PAF was added to feG incubated cells
Figure 1
feG and neutrophil migration. The dose response rela-
tionship for feG inhibition of PAF (10-9M) induced neutrophil 
migration. (mean ± SEM; n = 3–7). Statistically significant dif-
ferences (*P < 0.05) between the indicated values and the 
inhibition seen in absence of peptide.BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/3
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small, but significant, reductions in CD11b antibody
binding of 12%, 17% and 15% occurred with 10-10M, 10-
11M and 10-12M feG, respectively (Figure 3A). These mod-
est inhibitory effects actually reflect the inclusion of basal
antibody binding (see Figure 4A; control histogram) that
is not affected by feG. This basal, control binding was sub-
tracted from the total MFI values to yield a net change in
MFI (Net MFI). With this transformation (Figure 3B) the
inhibitory effects of feG on antibody binding were 25%,
34% and 35% for 10-10M, 10-11M and 10-12M feG, respec-
tively, which fell off to an insignificant inhibition of 16%
and 10% for 10-13M and 10-9M feG, respectively. The his-
tograms, in Figure 4A, show the increase in fluorescence
intensity over the control responses upon the addition of
PAF, as well as the inhibitory effect of feG on PAF en-
hancement of CD11b antibody binding. The neutrophils
were a homogeneous cell population as assessed by for-
ward and side-light scatter shown in the dot plot (Figure
4B).
Several other cell adhesion molecules on neutrophils were
examined (Table 1). feG did not alter the basal binding of
these antibodies. PAF (10-9M) elicited significant increas-
es in antibody binding for CD11b (97%) and CD14
(88%), and decreases for CD43 (-52%) and CD62L (-
53%). With PAF activated neutrophils, feG treatment de-
creased binding of antibodies for CD11b (17% at 10-
11M), and CD16b (33% at 10-11M), and when basal con-
trol binding was subtracted (Net MFI) the decreases were
34% and 164%, respectively. The greater than 100% re-
duction of MFI for CD16b reflects that reduction by feG of
MFI values below those of the control obtained in the
Figure 2
feG and neutrophil adhesion. Effects of feG on neutrophil 
adhesion. A. feG did not affect the basal adhesion of neu-
trophils to gelatin. B. At doses of 10-11M and 10-10M feG 
inhibited neutrophil adhesion to gelatin induced by 10-9M 
PAF. (mean ± SEM; n = 5). Statistically significant differences 
(P < 0.05): # greater than Control in panel (A); * less than no 
peptide.
Figure 3
feG and CD11b antibody binding to human neu-
trophils. Effects of feG on basal and PAF (10-9M) induced 
binding of CD11b antibody (mean ± SEM; n = 6). A. Total 
MFI is plotted against dose of feG. B. Net MFI (total MFI-con-
trol MFI in absence of PAF) is plotted against dose of feG. 
Statistically significant differences (*P < 0.05) from no peptide 
(0).BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/3
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absence of PAF or peptide, as illustrated in the histograms
in Figure 5. Several other markers on human neutrophils
were not affected by feG, and these include CD11a,
CD11c, CD14, CD18, CD43, CD62L, CD87 and CD162
(Table 1).
feG's inhibitory effects on binding of CD11b and CD16b
antibodies occurred only if the neutrophils were stimulat-
ed with PAF, since the peptide had no effect on the bind-
ing of these antibodies on neutrophils stimulated with IL-
8, LTB4, C5a (ZAP) or TNF (Table 2). Of these alternative
stimulants, only IL-8 and C5a increased binding of
CD11b antibody, and none altered the binding of CD16b
antibody. Furthermore, the inhibitory effects on CD11b
and CD16b antibody binding were specific for feG, since
the inhibition was absent with N- and C-terminally
blocked analogues, i.e. amino-terminal acetylation and
carboxyl-terminal amidation (Table 3). Furthermore, the
tripeptide feA, which was ineffective in reducing antigen-
induced contractions of rat sensitized ileum, a hallmark of
feG biological activity [20], did not affect antibody bind-
ing to CD11b and CD16b.
Figure 4
FACS analysis of CD11b antibody binding to isolated human blood neutrophils. A. Histograms of relative cell count 
for Isotype control (irrelevant, species-matched IgM antibody), and CD11b antibody (mouse anti-human IgG1, VIM 12 clone) 
for Control (no additions), PAF alone (10-9M), feG alone (10-11M) and feG in the presence of PAF. PAF increases fluorescence 
intensity relative to Control, and feG decreases the fluorescence intensity. Histograms are representative tracings. B. Dot plot 
of cell sample treated with 10-9M PAF showing homogenous nature of the isolated neutrophils. The dot plot is representative 
of cell samples for Control and feG treated cells.BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/3
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Effects of feG on binding of CD11b and CD16b antibodies
The reduction by feG of antibody binding for CD11b and
CD16b could be due to several factors which include, pre-
venting the mobilization of granule-stored intracellular
molecules, promoting their shedding from the cell
surface, or altering antibody binding without affecting the
amount of CD11b or CD16b expressed on the cell
membrane. We initially examined if the decrease in bind-
ing of CD11b and CD16b antibodies was also observed
with intracellular as well as cell surface localized mole-
cules. An increase in the binding of the isotype antibody
from 19.8 ± 2.9 to 42.7 ± 7.5 MFI units was seen when the
cells were fixed, although fixation did not affect basal and
PAF-stimulated binding of CD11b, with relative MFI for
fixed to non-fixed cells being 104% and 80% of control
values, respectively. In contrast, fixation markedly
reduced the binding of CD16b antibody with basal and
PAF-stimulated binding of the antibody to fixed cells be-
ing only 35% and 27% of that seen in non-fixed cells.
Consequently, only the effect of feG on intracellular
CD11b was evaluated. Figure 6 shows that feG reduced
binding of CD11b antibody to the cell surface, whereas
binding to the internal pool of this marker was not al-
tered. This result implies that feG alters primarily the
Figure 5
FACS analysis of CD16b antibody binding to isolated human blood eutrophils. A. Histograms of relative cell count 
for Isotype control (irrelevant, species-matched IgG antibody), and CD16b antibody (mouse anti-human IgMκ; 1D3 clone) for 
Control (no additions), PAF alone (10-9M), feG alone (10-11M) and feG in the presence of PAF. PAF only modestly increases 
fluorescence intensity relative to Control, and feG decreases the fluorescence intensity below those seen in Control. Histo-
grams are representative tracings. B. Dot plot of cell sample treated with 10-9M PAF showing homogenous nature of the iso-
lated neutrophils. The dot plot is representative of cell samples for Control and feG treated cells.BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/3
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binding of antibody to CD11b molecules located on the
surface of cells.
The suggestion that feG alters antibody binding was sup-
ported, at least for CD16b, by the observation that the
binding of a second CD16b antibody (LNK16 clone) was
not modified by feG, in contrast to the dose-dependent
decrease in binding of the 1D3 clone antibody (Figure 7).
Since the LNK16:IgG1 isotype ratio was not modified by
feG it appears that the peptide does not affect the amount
of CD16b on the surface of the neutrophil. feG may alter
the binding of the 1D3 antibody, by causing a change in
conformation of CD16b with obscuration of the binding
epitope for this antibody, but not for the LNK16 antibody.
CD11b and CD16 on rat neutrophils
Since feG was synthesized based on the sequence of a rat
peptide [5], but has potent activities on human neu-
trophils, we also examined the effects of this peptide on
circulating rat neutrophils. feG at concentrations from 10-
11M to 10-10M inhibited the binding of CD11b antibody
to rat neutrophils (Figure 8). With CD16 feG also gave the
bell-shaped dose-dependent inhibition (10-12M to 10-
10M) of antibody binding to isolated rat neutrophils.
Migration of rat neutrophils
A dose of 100 µg/kg of feG was used for these in vivo in-
vestigations since we had shown previously that this dose
provided optimal inhibition of allergic reactions in rats
[5]. Neutrophils were the exclusive cell recovered from
carrageenan soaked sponges. The cells were >98% viable
as determined by Trypan-blue exclusion. Addition of car-
rageenan to the sponge increased neutrophil counts by
approximately 3 fold from 7.2 ± 1.6 (× 105) to 20.0 ± 3.7
(× 105) cells/mg of sponge (Figure 9). Treatment of rats
with 100 µg/kg of intraperitoneal feG significantly
reduced by 42% to 11.7 ± 2.6 (× 105) neutrophils/mg of
sponge.
CD11b and CD16 antibody binding to rat peritoneal and 
blood cells
To investigate if a functional correlation exists between
the effects of feG on CD11b and CD16 during an inflam-
mation, these molecules were measured on blood and
peritoneal neutrophils isolated from ovalbumin-sensi-
tized rats that had been challenged with antigen after be-
ing treated with feG (100 µg/kg, per os). Basal binding of
CD11b to peritoneal and blood neutrophils, expressed as
MFI, was 1342 ± 102 and 367 ± 46, respectively (Figure
10A). The peptide feG reduced basal binding of CD11b to
896 ± 183 and 158 ± 29 for the peritoneal and blood neu-
trophils, respectively. The binding of CD11b on blood
cells was increased 1.8 fold by the antigen, whereas on
peritoneal cells the increase was only 1.2 fold. The inhib-
itory effect of feG, seen on the binding of CD11b under
basal conditions for both circulating and peritoneal cells,
was not observed in rats that received an antigen challenge
24 h previously.
With blood neutrophils, CD16 binding was not affected
by feG or by antigen challenge (Figure 10B). The 30% re-
duction of basal MFI for CD16b from 1552 ± 188 in
controls to 1092 ± 187 in feG-treated rats was maintained
in OA-exposed animals, with MFI in these challenged rats
being 1513 ± 158 in controls and 914 ± 134 in feG-treated
rats.
Discussion
The critical role played by neutrophils in controlling in-
fections and other inflammation, can lead to unwanted
collateral damage to adjacent cells and tissues. Thus, neu-
trophil activity needs to be rigorously controlled. The reg-
ulatory mechanisms, which for the most part are
mediated through cell surface membrane receptors, uti-
lize a variety of juxtacrine, paracrine, and endocrine
systems [11]. Some of the paracrine mechanisms involve
mediators emanating from the circulation (complement,
catecholamines, GM-CSF) and released from other
immune cells, (LTB4, PAF and TNF), or involve juxtacrine
mechanisms such as regulation of expression and affinity
of counter adhesion receptors, such as ICAM-1, on en-
dothelial cells [21]. Although some of the major endo-
crine influences on neutrophil function are
catecholamines and glucocorticoids, the current study
Figure 6
feG and intracellular CD11b. Binding of CD11b antibody 
to membrane (external) and granular (internal) pools of neu-
trophils was determined in untreated controls (black col-
umns), and in the presence of PAF alone (red columns), or 
PAF and feG (10-11M) (blue columns). Results are presented 
as mean ± SEM (n = 6) of MFI for CD11b. Statistically signifi-
cant differences (P < 0.05): # greater than control; * less than 
PAF.BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/3
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supports a previous suggestion [7] that hormones, elabo-
rated in an exocrine/endocrine submandibular gland, also
are potent modulators of neutrophil function.
This ability of salivary gland peptides to modify neu-
trophil function has important implications for both oral
and systemic health, because unregulated neutrophil
function can lead to serious problems with the soft tissues
of the mouth resulting in gingivitis [22], and can
contribute to ulcerous mucosal lesions in the stomach
[23]. Factors of salivary gland origin, such as NGF pro-
mote neutrophil chemotaxis, phagocytosis, superoxide
production and survival [24–28]. Another factor, en-
dothelial-monocyte-activating polypeptide-II, released
from salivary glands promotes monocyte endothelial cell
interactions [29]. The SMR1 C-terminal peptides, of
which feG is an example analogue, through their anti-mi-
gratory (Figures 1 &9) and anti-adhesive properties (Fig-
ures 2), may act to counter-balance and modulate the pro-
inflammatory factors elaborated by these glands. Unlike
NGF, which promotes numerous neutrophil functions,
the actions of feG are limited to cell migration and adhe-
sion, as superoxide production and phagocytosis were not
affected. It should be noted that the heptapeptide SGP-T
reduced superoxide production by human neutrophils
[7], although this inhibitory activity was not shared with
the truncated D-isomeric peptide.
Thus, rather than being an overall suppressive agent, feG's
effects on inflammation are limited to restricting neu-
trophil recruitment into a site of inflammation. This
mode of action would permit the anti-inflammatory
activity of neutrophils to proceed, but reduces collateral
cell and tissue damage by restricting the number of acti-
vated neutrophils participating in the inflammatory
response. Limiting neutrophil accumulation has impor-
tant implications in the treatment of asthma [6], intestinal
allergy [5] and possibly other inflammatory disorders. feG
may potentially be useful in counteracting some undesir-
able side effects of steroids in asthmatics. High dose ster-
oids in severe asthmatic patients do not alleviate airway
neutrophilia, and paradoxically corticosteroids enhance
neutrophil survival and exacerbate neutrophil activity,
possibly leading to unwanted effects of the steroids in
asthmatic patients [17]. Since the inhibition of neutrophil
function by feG is only partial, generally in the range of
30–40% and limited to PAF-activated cells, it is possible
that the peptide may act on a subpopulation of circulating
neutrophils which have a spectrum of ages and history of
prior activation or priming by chemotaxins or cytokines
[30,31]. Further studies are required to verify this hypoth-
esis or whether, alternatively, feG acts on only one arm of
a multi-pathway for cell activation used by PAF [32].
The mechanism employed by feG to inhibit neutrophil
function is unknown, although regulation of cell
adhesion molecules or accessory molecules appear to be
involved, in particular CD11b and CD16b (Table 1;
Figures 3 and 7). CD16b is discussed in more detail be-
low. Several important features of feG's actions relate to its
actions on the αβ2-integrins. The CD11 isoforms, dimer-
ize with CD18 [33] to form αLβ2-integrin (LFA-1; CD11a/
CD18), αMβ2-integrin (Mac-1; CD11b/CD18) and αXβ2-
integrin (p150, 95; CD11c/CD18). These heterodimers
are important to neutrophil binding and the inflammato-
ry process [34–36]. Since feG affects CD11b and has no
effect on CD11a, CD11c or CD18, it appears that the
peptide affects predominately the binding of CD11b anti-
body rather than promoting a loss of this integrin from
the cell. This altered antibody binding may reflect reduced
affinity of CD11b for its counter and accessory receptors.
A second point related to feG's actions αβ2-integrins is the
specificity shown for PAF stimulation. Stimuli, such as
PAF, LTB4, IL-8 and C5a activate neutrophils via attach-
ment to specific receptors on the cell surface [10], and elic-
it an increase in antibody binding to αM- and/or β1-
integrins on neutrophils (Table 2; and [37–41]). TNF does
not activate neutrophil functions directly, but rather acts
as a priming agent for chemotactic and proadhesive func-
tions [42,43], and this cytokine does not modify CD11b
expression (Table 2). The firm adhesion of rolling neu-
trophils on inflamed endothelium is dependent on β2
(CD18)-integrins, with CD11a/CD18 being more impor-
tant than CD11b/CD18 in neutrophil emigration at in-
flammatory sites as elicited by IL-8 and LTB4 [41,42].
CD11a and CD11c are expressed at lower levels on circu-
lating human neutrophils than CD11b (Table 2). Other
cell adhesion molecules, such as CD43, L-selectin
(CD62L) and CD162, which participate in neutrophil ad-
hesion and movement [44–46], were not explored further
since feG did not modify binding of these antibodies to
neutrophils (Table 1).
Other plasma membrane receptors, and in particular the
glycosylphosphatidylinositol (GPI)-anchored protein Fc-
γRIIIB (CD16b), are absolutely required for chemotaxis of
human neutrophils [47]. This activity of CD16b is ex-
plained, at least in part, by its ability to physically interact
with CD11b [48,49] to form a functional complex
[50,51]. The activation of chemotaxis, at least by fMLP, is
also associated with an up regulation and eventual
shedding of CD16b [52]. Our studies indicate that PAF ef-
fects may be the consequence of a CD11b-CD16b rela-
tionship, since the increased binding of antibodies to
both of these proteins by the lipid mediator was
prevented by feG (Table 1; Figures 3 &7). The differential
regulation by feG of 1D3 and LNK16 binding indicates
that the peptide, in some manner, alters the conformation
of CD16b such that the binding of 1D3 is reduced where-BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/3
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as that of LNK16 is not affected. This conclusion is sup-
ported by the observation that these two antibodies have
distinct binding epitopes on CD16b. LNK16 binds to C'β-
sheet region of CD16b which is located in the membrane-
proximal domain, whereas 1D3 binds to more distal FG
loop [53], which composes the major binding determi-
nant on this receptor. By altering FG loop conformation
feG may reduce the dimeric association of CD16b and
CD11b. Another GPI-linked protein, CD87 interacts with
plasma membrane integrins (β1, β2 and β3) in various
cell types [49], but does not participate in the actions of
feG since the peptide did not modify antibody binding to
this marker.
With rats feG reduced neutrophil migration (Figure 9)
and the expression of CD11b and CD16 on neutrophils
Table 1: Effects of feG on the binding of antibodies to cell adhesion and associated molecules in PAF-stimulated cells.
Antibody Isotype Control Control PAF PAF & feG1
% Change
CD11a 5.2 ± 0.62 27.7 ± 5.9 30.6 ± 4.5 34.6 ± 5.0 +11 ± 33
CD11b 4.2 ± 0.4 148.1 ± 12.8 291.6 ± 14.1# 242.1 ± 16.3* -17 ± 4 (-34)4
CD11c 5.7 ± 0.2 38.2 ± 6.8 52.4 ± 7.3 47.9 ± 6.0 -9 ± 5
CD14 5.8 ± 0.3 17.9 ± 1.8 33.7 ± 1.2# 32.5 ± 1.8 -4 ± 3
CD16b 19.8 ± 2.9 357.4 ± 55.4 450.7 ± 62.5 297.9 ± 53.2* -33 ± 7 (-164)4
CD18 4.6 ± 0.5 85.7 ± 3.5 95.6 ± 2.9 94.6 ± 2.1 -1 ± 3
CD43 2.9 ± 0.2 48.5 ± 5.7 23.3 ± 3.2† 22.4 ± 3.1 -4 ± 2
CD62L 4.5 ± 0.4 57.6 ± 4.8 27.1 ± 2.4† 29.2 ± 2.5 +8 ± 5
CD87 8.7 ± 1.9 40.7 ± 6.6 41.0 ± 3.0 44.1 ± 1.6 +7 ± 4
CD162 51.0 ± 13.9 307.4 ± 40.0 222.7 ± 23.9 219.2 ± 46.4 -2 ± 3
1Concentration of feG = 10-11M. 2 Values expressed as mean ± SEM of Mean Fluorescence Intensity for n = 4–14. 3 Percent change between PAF 
and PAF & feG. 4 Percent change after subtraction of Control MFI from that of PAF and PAF & feG (Net MFI). Significance (P < 0.05): # greater than 
Control; * = less than PAF alone; † less than Control.
Table 2: Effects of various inflammatory agents on the binding of CD11b antibody to human neutrophils.
CD11b CD16b
Stimulant Control Stimulant Stimulant & feG1 Control Stimulant Stimulant & feG
PAF2 148.1 ± 12.83 291.6 ± 14.1# 242.1 ± 16.3* 357.4 ± 55.4 450.7 ± 62.5 291.9 ± 80.3*
IL-8 283.1 ± 36.0 455.9 ± 39.8# 459.5 ± 49.9 490.8 ± 49.6 551.6 ± 68.2 516.5 ± 59.2
LTB4 325.8 ± 72.8 367.4 ± 69.1 425.9 ± 74.4 555.6 ± 117.3 588.6 ± 117.3 565.3 ± 94.6
C5a 227.4 ± 35.4 415.1 ± 36.8# 445.1 ± 29.9 433.7 ± 55.2 447.1 ± 41.5 419.3 ± 53.4
TNF 260.2 ± 28.3 270.3 ± 28.6 297.5 ± 33.7 528.2 ± 67.7 467.7 ± 44.3 490.0 ± 50.7
1Concentration of feG = 10-11M. 2Concentrations of stimulants: PAF = 10-9M; IL-8 = 10-9M; LTB4 = 10-9M; C5a = 1%; TNF = 5ng/ml. 3 Values 
expressed as mean ± SEM for n = 3–11. Significance (P < 0.05): # greater than Control; * less than Stimulant alone.
Table 3: feG inhibition of antibody binding to CD11b and CD16b requires free N-terminal amide and C-terminal carboxyl groups.
Condition CD11b CD16b
Basal 220.2 ± 17.72 401.1 ± 55.2
PAF (10-9M) 381.9 ± 23.0 479.2 ± 62.1
PAF & feG1 278.1 ± 23.7* 291.9 ± 80.3*
PAF & feG(NH2) 381.5 ± 54.7 446.9 ± 69.5
PAF & AcfeG 350.1 ± 61.2 425.4 ± 57.7
PAF & feA 384.8 ± 33.7 458.3 ± 36.6
1Concentrations of peptides = 10-11M. 2 Values of Mean Fluorescence Intensity expressed as mean ± SEM for n = 4–7. Significance: * less than PAF 
alone.BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/3
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(Figure 8), even though rat CD16 has a transmembrane
domain like human CD16a, and is not GPI-linked [54].
However, a direct relationship between CD11b and
CD16, at least in terms of modulating the binding of an-
tibodies to these markers on rat neutrophils, is questioned
by the dissociation of feG effects on the binding of CD11b
and CD16 antibodies to rat neutrophils obtained from al-
lergen-challenged rats (Figure 10). Aside from species
differences this dissociation of feG effects on the binding
of CD11b and CD16 antibodies could reflect phenotypic
changes in the cells following antigen challenge. Nonethe-
less, even in the absence of an effect of feG on neutrophil
CD11b obtained from OA-challenged animals, the
observed change in CD16 suggests that the IgG-receptor is
an important participant in feG regulation of neutrophil
function after exposure to allergen.
Conclusions
This study has established that the tripeptide feG, a deriv-
ative of a 7 amino acid anti-inflammatory peptide isolated
from salivary glands of rats, is a potent (picomolar) inhib-
itor of neutrophil movement and chemotaxis on human
and rat neutrophils. feG reduces the binding of CD11b
and CD16b antibodies to neutrophils, and may exerts its
anti-inflammatory effects by modifying the activity of
these molecules resulting in impaired neutrophil migra-
tion into a site of inflammation. feG may have utility in
modulating the severity of a variety of inflammatory
conditions.
Methods
Materials, chemicals, peptides and antibodies
Unless otherwise specified all antibodies were against hu-
man proteins. The following antibodies were used: anti-
rat CD11b (clone WT.5; Pharmingen, San Diego, CA);
CD11a (clone MEM-25; mouse IgG1; Caltag, Burlingame,
CA); CD11b (clone VIM 12; mouse IgG1; Caltag); CD11c
(clone BU15; mouse IgG1; Caltag); CD16, (clone B-E16;
mouse IgG1; Medicore, Montreal, QC); CD16b (clone
1D3; mouse IgMκ; Beckman Coulter Canada Inc., Missis-
sauga, ON); CD16 (clone LNK16; mouse IgG1; Advanced
ImmunoChemical Inc, Long Beach, CA); CD18 (clone
L130, mouse IgG1; Pharmingen); CD87 (clone VIM5;
mouse IgG1; Pharmingen); CD162 (PSGL-1, P-selectin
glycoprotein ligand-1; clone KPL-1; Mouse IgG1κ,
Pharmingen); affinity purified FITC goat anti-mouse IgG
(ESBE). Products obtained from Sigma Chemicals Inc. (St.
Louis, MI) were: aluminum hydroxide (Al(OH)3); bovine
serum albumin (BSA); cytochrome C; superoxide dis-
mutase; ovalbumin (OA); Coomassie Brilliant Blue R250;
platelet activating factor (PAF); phorbol myristate acetate
(PMA); N-formyl-methionyl-leucyl-phenylalanine (fM-
LP); paraformaldehyde. Other products used were: fetal
bovine serum (FBS) (Cansera International Inc., Toronto,
ON), tumour necrosis factor (TNF) and interleukin-8 (IL-
8) (Research Diagnostics Inc.,Flandere,NJ); HTMT
dimaleate (6-[2-(4-Imidazolyl)ethylamino]-N-(4-trifluor-
omethylphenyl)-heptanecarboxamide) (Tocris Cookson
Inc., Ellisville, MO), and Hanks' balanced salt solution
Figure 7
feG and the binding of different antibodies to CD16b. 
The dose response relationship for the binding of two differ-
ent antibodies against CD16b, the 1D3 and LNK16 clones, 
to human neutrophils. The percent change in MFI relative to 
PAF (10-9M) is plotted against dose of feG. Data presented 
as mean ± SEM for n = 6–8. Statistically significant differences 
(*P < 0.05) from no peptide (0).
Figure 8
feG and binding of CD11b and CD16 antibodies to rat 
neutrophils. A dose response relationship for the inhibition 
by feG of the binding of CD11b and CD16 antibodies to PAF 
(10-9M) stimulated rat neutrophils (mean ± SEM; n = 6). The 
percent change in MFI relative to PAF (10-9M) is plotted 
against dose of feG. Statistically significant differences (*P < 
0.05) from PAF in the absence of peptide.BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/3
Page 10 of 14
(page number not for citation purposes)
(HBSS; Gibco BRL, Grand Island, NY). Core Laboratories,
Queens University, Kingston, ON synthesized feG. Its
composition was verified by amino acid analysis.
Phosphate buffered saline (PBS) had the following com-
position (mM): NaCl (137), KCl (2.7), Na2HPO4 (8.1),
KH2PO4  (1.47), CaCl2  (1.19,) MgCl2  (0.54), glucose
(7.5). The chemoattractant (PAF at 10-9M) was prepared
immediately prior to use with glass tubes and Hamilton
syringes to its final concentration in HBSS containing
0.1% BSA.
Isolation of human neutrophils
Neutrophils were isolated from the blood of normal
healthy volunteers as described previously [55]. The
blood (20 mL) was collected onto 4 mL acid citrate dex-
trose (ACD; 22.0 g/L trisodium citrate, 8.0 g/l citric acid,
24.5 g/l dextrose) as an anti-coagulant. The erythrocytes
were sedimented with dextran (6% dextran in 0.9% NaCl;
10 mL/20 mL blood) and the remaining red blood cells in
the plasma were subjected to a 5 min cold lysis using 155
mM NH4Cl, 10 mM KHCO3, 1 mM disodium EDTA, pH
7.4. The cells were then centrifuged at 150 g for 12 min in
a Beckman J6-MC using a JS 4.2 Rotor. The supernatant
was discarded and the pellet was resuspended in cold lysis
buffer and washed in PBS. Granulocytes were then
isolated using Ficoll separation to a purity of >98% as de-
termined by differential staining with Geimsa-Wright
stain. The cells were stored on ice until just before use, at
which point they were spun and resuspended at a final
concentration of 107 cells/mL in HBSS. Neutrophil viabil-
ity, assessed by Trypan blue exclusion, was >97%.
Incubation with feG and agonists
Neutrophils were preincubated at room temperature with
peptides in doses ranging from 10-7 to 10-14M for 5 min
(unless otherwise indicated) prior to adding stimulating
agents for 10 min at 37°C. Stimulants and concentrations
used, which were optimized in preliminary experiments,
were: PAF (10-9M), IL-8 (10-9M), TNF (5 ng/mL), or
LTB4(10-9M).
Antibody binding to cell markers
Neutrophils were centrifuged at 200 g for 6 min at 4°C.
The supernatant was decanted and 50 µl of antibody, at
the appropriate dilution, added to the pellet followed by
gentle vortexing. The appropriate isotype controls were
prepared. The neutrophils were incubated with antibody
for 30 min at 4°C in the dark. Following this incubation
1 mL of cold PBS was added and the cells centrifuged at
180 g for 6 min at 4°C. The supernatant was decanted
carefully, and 300 µL of PBS added to the neutrophils,
which were then read with a Fluorescence Activated Cell
Sorter (FACS; BD Biosciences, Lexington KY). The effects
of the peptides on the binding of antibodies to cell surface
molecules were evaluated by determining the changes in
mean fluorescence intensity (MFI) of cells incubated in
the presence of peptide and PAF and those incubated in
the presence of PAF alone, after subtracting the
background (Control; MFI expressed in cells incubated in
absence of PAF and peptide).
Cell migration
Neutrophils were kept at 4°C in calcium and magnesium
free PBS at 1 × 107 cells/mL. Immediately prior to use the
neutrophils were diluted to 2.5 × 106 cells/mL, and aliq-
uoted to 500 µL Eppendorf microfuge tubes and the ap-
propriate amount of peptide was added for incubation at
room temperature for 5 min. After this preincubation 500
µL HBSS was added to the cells and the tube mixed gently.
Chemotaxis was performed with Costar plates (Corning
Life Sciences, Acton MA) that were coated previously with
1% gelatin in PBS (inserts – 200 µl and wells – 800 µl) for
at least 1 h at 37°C. A volume of 1.3 mL of chemoattract-
ant was added to the bottom well and 400 µl of cell sus-
pension to the inserts. The inserts were placed carefully
into the wells, making sure no air bubbles were trapped
between the insert and the chemoattractant. The plates
were then incubated at 37°C for 1 h to allow cell migra-
tion to occur. Upon removal of the plates from the incu-
bator, they were gently shaken from side to side to
dislodge any cells adherent to the bottom of the insert.
The insert was then discarded and 1.2 mL of 2% Phos-
phate Buffered Formalin was added to each well. After a
10 min fixation at 4°C, the plates were centrifuged at 300
g for 10 min and the supernatant was then discarded. The
Figure 9
Chemotaxis of rat neutrophils. Inhibition of the accumu-
lation of neutrophils into a subcutaneously implanted carra-
geenan (Carr)-soaked sponge by 100 µg/kg of feG 
administered intraperitoneally. (mean ± SEM; n = 6–10). Sta-
tistically significant differences (P < 0.05): # greater than con-
trol; * less than Carr.BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/3
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cells were resuspended in 300 µL of PBS buffer and count-
ed on a hemocytometer.
Superoxide production
Neutrophils (106) were suspended in PBS containing 1.5
mM cytochrome C and incubated at 37°C. Each sample
was read along with a reference sample containing 1440
units of superoxide dismutase in a spectrophotometer
(Hitachi, U200 spectrophotometer). The rate of superox-
ide production was determined in response to 10-9M PAF
after subtracting the reference value obtained in the pres-
ence of superoxide dismutase.
Phagocytosis assay
Phagocytosis of flourescein-labeled Staphylococcus aureus
(Bioparticles; Molecular Probes, Eugene OR) was carried
out according to manufacturer's instructions. The Biopar-
ticles were opsonized with pooled human serum. Control
tubes were kept at 4°C to monitor adherence of the la-
beled bacteria to neutrophils in the absence of uptake,
while phagocytosis was performed at 37°C for 60 min.
Samples were then placed immediately at 4°C and mixed
with FITC quench-buffer to eliminate fluorescence from
bacteria sticking to the neutrophil cell surface. The assay
was performed in duplicate and analyzed by flow cytom-
etry. Ten thousand events were counted to assess the per-
centage of neutrophils that had phagocytosed S. aureus
and the mean fluorescence intensity (MFI) – a measure of
the number of bacteria taken up per cell was determined.
Data were expressed as the neutrophil phagocytic index:
Phagocytic index = % phagocytic neutrophils × MFI.
Neutrophil fixation and permeabilization
To visualize intracellular antigens for CD11b and CD16b
antibodies, isolated neutrophils were fixed and permeabi-
lized using a Fix & Perm Cell Permeabilization kit (Calt-
ag). Upon completion of control (no fixation or
permeabilization), fixation only and fixation and perme-
abilization procedures, antibody was added for 30 min at
4°C in the dark. The cells were then washed with 1 mL of
cold PBS and centrifuged at 180 g for 6 min at 4°C. The
supernatant was decanted carefully, and 300 µL of PBS
added to the cells. MFI determined by flow cytometry. The
amount of internal antigen binding sites was determined
by subtracting the MFI obtained from fixation only versus
fixation and permeabilization values.
Adhesion assay
Isolated blood neutrophils at a concentration of 0.5 × 106
cells/mL were plated on coverslips coated with 1% gelatin.
Neutrophil adhesion, performed in the presence of PAF
(10-9 M), was allowed to proceed for 30 and 60 min at
37°C. Non adherent cells were rinsed off the cover slips
with ice-cold HBSS and adherent cells were fixed for 5 min
in 4% paraformaldehyde at room temperature, and
stained with Wright's stain for counting.
Experimental animals
The University of Calgary Animal Care Committee ap-
proved all experiments in accordance with the guidelines
of the Canadian Council on Animal Care. Male, Sprague-
Dawley rats (Faculty of Biosciences, The University of Cal-
gary) weighing 250–350 g were used. The rats were sensi-
tized by intraperitoneal injection of 10 mg of OA and 10
mg of Al(OH)3 in saline as an adjuvant, and used 5 weeks
after sensitization [5].
Figure 10
CD11b and CD16b antibody binding to rat neu-
trophils. Effect of feG on the binding of CD11b (A) and 
CD16 (B) antibodies to rat peritoneal (black bars) and blood 
(red bars) neutrophils. (mean ± SEM; n = 4–7). Four groups 
of ovalbumin (OA)-sensitized rats were used: unchallenged 
and saline treated (Cont), unchallenged and feG-treated 
(feG), challenged and saline-treated (OA), and challenged and 
feG-treated (OA+feG). Statistically significant differences (P 
< 0.05) where # indicates greater than OA-challenged and * 
indicates less than Cont, and ** less than OA.BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/3
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Preparation of rat leukocytes
Blood was collected by cardiac puncture into a 10 mL sy-
ringe from rats anesthetized with halothane. The blood
was diluted with approximately 30 mL of PBS in a 50 mL
polypropylene centrifuge tube, and spun at 300 g for 15
min at 20°C. The buffer was carefully decanted from the
pellet, and the red blood cells were lysed (0.15 M NH4Cl)
for 3 min at room temperature. After a second spin at 200
g for 10 min at 20°C, the supernatant was discarded and
the pellet washed with PBS buffer and spun again at 200
g for 10 min at 20°C. The supernatant was then discarded
and the cells resuspended in 1 mL of PBS buffer, and lay-
ered onto Ficoll-Paque and spun at 300 g for 15 min at
20°C. The neutrophil numbers were determined using
Trypan Blue exclusion on a hemocytometer. Cell
differentials were determined on cell smears stained with
May-Grünwald-Giemsa stain.
To isolate peritoneal leukocytes 10 mL of 0.9% sterile sa-
line was injected intraperitoneally with a 20-gauge needle
into halothane anesthetized rats and the abdomen mas-
saged gently. After a clean laparotomy the peritoneal fluid
(7 to 10 mL) was recovered and placed into a 50 mL poly-
propylene centrifuge tube and diluted to 30 mL with PBS
buffer. The cells were then prepared as described for blood
leukocytes.
Cell surface markers on rat blood and peritoneal 
neutrophils
The effects of OA-sensitization and peptide treatment on
the binding of CD11b and CD16 antibodies to circulating
and peritoneal leukocytes were examined in three groups
of rats: one group received 0.9% saline (1 µL/g) by gavage
while treated rats received either 50 mg of OA, or both OA
and feG (100 µg/kg) intragastrically 24 h prior to isolation
of circulating and peritoneal leukocytes. The cells were
prepared as described above and incubated with antibody
for 30 min at 4°C in the dark. Following this incubation
1 mL of cold PBS was added and the tubes centrifuged at
180 g for 6 min at 4°C. The supernatant was decanted
carefully, 300 µl of PBS added to the neutrophils and they
were then read with a Fluorescence Activated Cell Sorter
(FACS). Their characteristic forward and side scatter iden-
tified neutrophils.
In vivo chemotaxis of rat neutrophils
To study the chemotaxis of rat neutrophils in vivo small
sponges (0.5 cm3) soaked in either 0.9% saline or 0.5%
carrageenan were inserted subcutaneously in the intras-
capular region of halothane anesthetized rats. To implant
the sponge a 2–3 cm incision was made dorsally between
the shoulder blades and connective tissue was cleared
from the exposed area. The skin was then closed with su-
tures of 3–0 Dexon thread. Twenty-four h after implanta-
tion, and under halothane anesthesia the sponges were
removed from their subcutaneous sites and the fluid they
contained was squeezed into a test tube. Following cen-
trifugation at 300 g for 10 min the exudate was decanted,
the neutrophils were suspended in 4 mL of 0.9% saline,
and their number determined using a Coulter Counter
ZM (Beckman Coulter Canada Inc., Mississauga, ON).
Data analysis
Results are expressed as means ± SEM, and N is the
number of animals or separate isolations of human neu-
trophils. Statistical significance of differences between
means was determined at P < 0.05 using one-way analysis
of variance (ANOVA). If the F-test statistic warranted fur-
ther analysis, significance between the means of two
groups was determined using the Student's t-test.
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